Skip to main content

Table 1 Treatment outcome of AL and AS/AQ at D28.

From: Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: A report from three study sites in sub-Saharan Africa

Study site

Drug used

Enrolled

Parasitaemic patients on D0 N (%)

Patients seen at D28 N (%)

Crude parasitological failure (%)

Geometric mean parasite density D28 (p/μl)

PCR adjusted failure rate*

PCR adjusted cure rate

Badeku & Ojoku/Ajia Nigeria

AL

432

306 (70.8%)

C.I. 67%–75%

184 (60.1%)

77/184 (41.8%)

C.I. 35%–49%

2835

14/154 (9.1%)

90.9%

C.I.

86%–95%

Ejisu-Juaben, Ghana

AS/AQ

848

603 (71.1%)

C.I. 68%–74%

205 (34%)

57/205 (27.8%)

C.I. 22%–34%

15080

17/197 (8.6%)

91.4%

C.I.

87%–95%

Bugiri, Uganda

AL

460

280 (60.9%)

C.I. 56%–65%

217 (77.5%)

8/217 (3.7%)

C.I. 1.2%–6.2%

N/A

6/216 (2.8%)

97.2%

C.I.

95%–99%

  1. *= Samples that could not be classified by PCR were excluded from the analysis
  2. AL = artemether-lumefantrine
  3. AS/AQ = artesunate-amodiaquine